Aurora, Colorado, USA, November 18, 2026
Researchers at the Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz, have reported encouraging findings from a Phase 2 clinical trial evaluating tofacitinib, a Janus kinase (JAK) inhibitor, in adolescents and adults with Down syndrome. The study found that treatment reduced excessive immune activity and improved certain inflammatory skin conditions, including hidradenitis suppurativa and alopecia areata. Published in Cell Reports Medicine, the research also identified preliminary changes in selected neurobehavioral assessments and biomarkers associated with brain health and Alzheimer’s disease. The findings provide new evidence supporting the investigation of immune-system dysregulation as a potential therapeutic target in Down syndrome. However, researchers emphasise that further controlled clinical trials are necessary to establish whether these findings translate into meaningful neurological benefits.
Tofacitinib Targets Excessive Immune Activity in Down Syndrome
Down syndrome is caused by an additional copy of chromosome 21, which contains genes involved in regulating immune responses. This genetic difference can contribute to increased interferon signalling and chronic immune-system overactivity, potentially influencing several health conditions experienced by people with Down syndrome. Researchers at the Crnic Institute investigated whether reducing this excessive immune signalling could help address associated inflammatory complications. The study evaluated tofacitinib, a JAK inhibitor that blocks specific signalling pathways involved in immune responses and inflammation. By targeting these pathways, the treatment aims to reduce abnormal inflammatory activity without broadly suppressing normal immune function. The research team enrolled adolescents and adults with Down syndrome who also had inflammatory skin conditions, including hidradenitis suppurativa and alopecia areata. Participants received tofacitinib twice daily for an initial 16-week treatment period, with an optional extension allowing treatment for up to 40 weeks. The trial incorporated safety monitoring, dermatological evaluations, blood-based molecular analyses and neuropsychological assessments to examine treatment effects across multiple areas.
Phase 2 Trial Shows Reduced Inflammation and Skin Improvements
The study met its predefined safety endpoint, with researchers reporting a safety profile broadly consistent with observations in the general population. Blood analyses demonstrated significant reductions in interferon activity, inflammatory cytokine scores and inflammation-associated metabolites, including quinolinic acid, a compound associated with neurotoxic effects. Additional analyses of gene expression, circulating proteins and metabolites indicated that tofacitinib modified specific inflammatory pathways rather than completely shutting down immune responses. Participants also experienced improvements in certain inflammatory skin conditions. These included hidradenitis suppurativa, which can cause painful inflammatory skin lesions, and alopecia areata, an autoimmune condition associated with hair loss. Improvements were assessed using standardised clinical measurements and dermatology-related quality-of-life evaluations. The findings suggest that targeting JAK signalling may help address some inflammatory complications associated with Down syndrome. Nevertheless, JAK inhibitors have known safety risks, and the study does not eliminate the need for continued monitoring and larger investigations to understand long-term safety in this population.
Preliminary Brain Health Findings Open New Research Directions
Alongside the inflammatory and dermatological findings, researchers observed encouraging changes in selected tests measuring attention, memory, vocabulary and behaviour. Some participant- and caregiver-reported measures of well-being also showed favourable changes. The study further identified improvements in certain biological markers associated with neurological function and Alzheimer’s disease. These observations could help researchers investigate the relationship between chronic immune overactivity, inflammation and brain health in people with Down syndrome. However, the neurological findings must be interpreted cautiously. The Phase 2 study was an open-label, single-arm trial without a placebo control group, meaning researchers cannot determine whether the observed neurobehavioral changes were directly caused by tofacitinib. Practice effects and other factors may have influenced assessment results. The investigators therefore describe these findings as preliminary rather than proof that the medication improves cognition. Researchers have also launched a separate clinical trial focused on Down Syndrome Regression Disorder, a condition involving sudden loss of neurological function. Results from this follow-up research are expected in 2027.
The study builds on the Crnic Institute’s Human Trisome Project, which investigates molecular and immune-system changes associated with Down syndrome. Funding support included the National Institutes of Health INCLUDE Project, the Global Down Syndrome Foundation and other research contributors. The findings represent an important research milestone in exploring treatments that address underlying biological mechanisms rather than individual symptoms alone. Tofacitinib is not approved specifically for Down syndrome, and the results do not establish a general treatment recommendation for people with the condition. Larger, randomised, placebo-controlled studies will be needed to confirm clinical benefits, identify appropriate patient groups and evaluate long-term safety. The research nevertheless provides a foundation for further investigation of immune-targeted therapies and their potential role in improving health outcomes for people with Down syndrome.
Source: University of Colorado Anschutz press release



